Details
Stereochemistry | EPIMERIC |
Molecular Formula | C13H12O6 |
Molecular Weight | 264.2308 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(O)=C2C(=O)OC(=CC2=C1)C(C)C(O)=O
InChI
InChIKey=BPZCXUROMKDLGX-UHFFFAOYSA-N
InChI=1S/C13H12O6/c1-6(12(15)16)10-4-7-3-8(18-2)5-9(14)11(7)13(17)19-10/h3-6,14H,1-2H3,(H,15,16)
Molecular Formula | C13H12O6 |
Molecular Weight | 264.2308 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
1H-2-BENZOPYRAN-3-ACETIC ACID, 8-HYDROXY-6-METHOXY-Α-METHYL-1-OXO- (NM-3) is an orally bioavailable antiangiogenic isocoumarin with potential antineoplastic activity. NM-3 inhibits vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor, thereby inhibiting endothelial cell proliferation. NM-3 induces apoptosis by a mechanism involving reactive oxygen species. In human MCF-7 and ZR-75-1 breast cancer cells, NM-3 induces the p21 cyclin-dependent kinase inhibitor, cell cycle arrest at G1-S-phase, and necrotic cell death. NM-3 has been used in trials studying the treatment of solid tumours.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) induces lethality of human carcinoma cells by generation of reactive oxygen species. | 2001 Nov |
|
Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo. | 2007 Jan 28 |
|
Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells. | 2007 Mar 28 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17278215
Mice: NM-3 was injected peritoneally at the dose of 10 mg/kg, 20 mg/kg or 40 mg/kg every other day for 5 wk, combined with carboplatin (5 mg/kg) every third day for 4 wk. As controls of combined treatment, another 4 groups of mice were injected with either NM-3 at 10 mg/kg, 20 mg/kg or 40 mg/kg, or with carboplatin alone (5 mg/kg).
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12467237
To assess the effects of NM-3 on cell proliferation and survival, MCF-7 breast carcinoma cells were treated with 100–400 ug/ml NM-3 for 24 and 48 h. The results demonstrate adose- and time-dependent inhibition of cell growth. o determine whether NM-3 affects clono-genic survival, cells were treated for 48 h and then culturedfor 10–14 days. Assessment of colonies demonstrated that NM-3 decreases clonogenicity of MCF-7 cells with an IC50 of 180 ug/ml. Similar results were found for ZR-75-1cells (IC50, 180 ug/ml).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:00:57 GMT 2023
by
admin
on
Sat Dec 16 05:00:57 GMT 2023
|
Record UNII |
5797K23F95
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1971
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12818
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
5797K23F95
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
DTXSID10939433
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
C1888
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
181427-78-1
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY | |||
|
5493470
Created by
admin on Sat Dec 16 05:00:57 GMT 2023 , Edited by admin on Sat Dec 16 05:00:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |